Actinium Pharmaceuticals Inc., of New York, reported interim data from the ongoing phase I/II trial of Actimab-A, its radiolabeled antibody, in older patients with newly diagnosed acute myeloid leukemia (AML), including median overall survival (OS) of the seven secondary AML patients (with prior myelodysplastic syndrome) of 9.1 months, compared to historical norms of typically two months to five months.